ClinicalTrials.gg
CompletedNCT01521494Updated Aug 23, 2018Results posted

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

A Phase 2 interventional study of PA21 and PA21 in Chronic Kidney Disease Requiring Hemodialysis, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-08-23.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
183
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.

Enrollment
10th of 36
183 · median 117
Started
2012
with 1 other
Phase 2
11 of 41
none open now
Registered
16th of 41
by date
Lead sponsor
5 of 41
Kissei Pharmaceutical Co., Ltd.

Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 10th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2012, is one of 11 in phase 2, and was the 16th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Hyperphosphatemia with a site in Japan, or all of them as a file.
02

Study summary

To investigate dose-response efficacy and safety in hemodialysis patients with hyperphosphatemia.

03

Conditions studied

  • Chronic Kidney Disease Requiring Hemodialysis

Browse trials for

Keywords

  • Hemodialysis
  • Hyperphosphatemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age 20 or older, regardless of gender.
  • Receiving stable maintenance hemodialysis 3 times a week.
  • Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.

Exclusion criteria

Exclusion Criteria:

  • Patients having history of a pronounced brain / cardiovascular disorder.
  • Patients having severe gastrointestinal disorders.
  • Patients having severe hepatic disorders.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
183 participants (actual)

Study arms

  • Experimental
    PA21 750 mg/day

    Drug: PA21

  • Experimental
    PA21 1500 mg/day

    Drug: PA21

  • Experimental
    PA21 2250 mg/day

    Drug: PA21

  • Experimental
    PA21 3000 mg/day

    Drug: PA21

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment.

    Changes in serum phosphorus concentrations from baseline to the end of treatment were adjusted by serum phosphorus concentration at baseline.

    Time frame: 6 weeks

Secondary outcomes

  1. Change From Baseline in Serum Calcium Concentrations.

    Time frame: 6 weeks

  2. Change From Baseline in Serum Intact-PTH Concentrations.

    Time frame: 6 weeks

07

Results

Posted Aug 23, 2018

Participant flow

Participant flow — Overall Study
MilestonePA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlacebo
Started3936353637
Completed3731231530
Not completed2512217
Withdrew: Adverse event12962
Withdrew: Lack of efficacy00002
Withdrew: Withdrawal by subject11020
Withdrew: Decrease in serum phosphate023120
Withdrew: Decrease in serum calcium00011
Withdrew: Physician decision00002

Outcome measures

PrimaryChange From Baseline in Serum Phosphorus Concentrations at the End of Treatment.

Changes in serum phosphorus concentrations from baseline to the end of treatment were adjusted by serum phosphorus concentration at baseline.

Time frame:
6 weeks
Reported as:
Least squares mean · mg/dL
Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment.
mg/dLPA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlacebo
Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment.-1.84 (-2.23 to -1.44)-2.59 (-3.01 to -2.17)-3.17 (-3.60 to -2.74)-3.78 (-4.20 to -3.36)0.14 (-0.26 to 0.55)
SecondaryChange From Baseline in Serum Calcium Concentrations.
Time frame:
6 weeks
Reported as:
Mean · mg/dL
Change From Baseline in Serum Calcium Concentrations.
mg/dLPA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlacebo
Change From Baseline in Serum Calcium Concentrations.0.20 ± 0.340.16 ± 0.330.38 ± 0.440.38 ± 0.39-0.09 ± 0.31
SecondaryChange From Baseline in Serum Intact-PTH Concentrations.
Time frame:
6 weeks
Reported as:
Mean · pg/mL
Change From Baseline in Serum Intact-PTH Concentrations.
pg/mLPA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlacebo
Change From Baseline in Serum Intact-PTH Concentrations.-35.2 ± 89.8-45.6 ± 79.2-97.0 ± 92.7-86.5 ± 104.021.5 ± 82.5

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PA21 750 mg/Day0/39 (0%)1/39 (2.6%)13/39 (33.3%)
PA21 1500 mg/Day0/36 (0%)2/36 (5.6%)11/36 (30.6%)
PA21 2250 mg/Day0/35 (0%)2/35 (5.7%)19/35 (54.3%)
PA21 3000 mg/Day0/36 (0%)1/36 (2.8%)20/36 (55.6%)
Placebo0/37 (0%)1/37 (2.7%)11/37 (29.7%)
Most frequent serious events
Most frequent serious events
EventPA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlacebo
Brain stem infarctionNervous system disorders0/390/361/350/360/37
Intracranial aneurysmNervous system disorders0/390/361/350/360/37
Liver abscessInfections and infestations0/391/360/350/360/37
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/391/360/350/360/37
Angina pectorisCardiac disorders0/390/360/351/360/37
Peripheral arterial occlusive diseaseVascular disorders0/390/360/350/361/37
Cerebral infarctionNervous system disorders1/390/360/350/360/37
Cardiac failure congestiveCardiac disorders1/390/360/350/360/37
Most frequent other events
Most frequent other events
EventPA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlacebo
DiarrhoeaGastrointestinal disorders6/396/3613/3515/367/37
NasopharyngitisInfections and infestations5/395/363/353/364/37
ContusionInjury, poisoning and procedural complications0/390/360/354/360/37
ConstipationGastrointestinal disorders0/391/362/352/361/37
HaemorrhoidsGastrointestinal disorders0/390/362/350/360/37
Pain in extremityMusculoskeletal and connective tissue disorders0/391/362/350/360/37
Abdominal painGastrointestinal disorders0/390/360/352/360/37
FlatulenceGastrointestinal disorders0/390/360/351/362/37
InsomniaPsychiatric disorders2/390/360/350/360/37
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders2/390/360/350/360/37

Baseline characteristics

Total of 5 patients were excluded from analysis because they failed to have primary endpoint.

Age, Continuous
Age, Continuous(years)PA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlaceboTotal
Mean59.4 ± 10.463.8 ± 12.061.9 ± 10.561.4 ± 11.260.8 ± 10.261.4 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)PA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlaceboTotal
Female121210151463
Male2723231923115
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlaceboTotal
American Indian or Alaska Native000000
Asian3935333437178
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White000000
More than one race000000
Unknown or Not Reported000000
Dialysis vintage
Dialysis vintage(months)PA21 750 mg/DayPA21 1500 mg/DayPA21 2250 mg/DayPA21 3000 mg/DayPlaceboTotal
Mean77.6 ± 67.585.1 ± 60.795.8 ± 81.991.5 ± 58.671.0 ± 45.083.7 ± 63.5
08

Study locations

1 site
  • Japan
    Multiple Locations, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Jul 2012, 5 months.

Results were first posted in Aug 2018, 6 years 1 month after primary completion.

Of 13 phase 2 interventional studies under Hyperphosphatemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 10. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2012
First posted
Jan 30, 2012
StartActual
Jan 11, 2012
Primary completionActual
Jul 3, 2012
CompletionActual
Jul 3, 2012
Results first posted
Aug 23, 2018
Last update
Aug 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01521494
Responsible party
Sponsor
First posted
Jan 30, 2012
Start date
Jan 11, 2012
Primary completion
Jul 3, 2012
Completion
Jul 3, 2012
Results posted
Aug 23, 2018
Last update
Aug 23, 2018

Study contacts

Tatsuro Takei
study director · Clinical Development Department, Kissei pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA21

Start the discussion